Effect of Early Systemic Stabilization Therapy on Recent Onset Vitiligo

Vitiligo is a distressing disorder of depigmentation. In spite of multiple successful therapeutic regimens, disease relapse remains a challenge to patients and physicians. Most guidelines consider systemic treatments only in rapidly progressive disease with wider surface areas. This delay in halting the immune attack, may give the chance for further disease progression as well as establishment of resident memory T cell population predisposing to future disease relapses. The aim of this study was to assess the ability of early systemic therapy of localized (<2% BSA), recent onset (<6 months) vitiligo to control disease activity and minimize the possibility of recurrence.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vitiligo Hypopigmentation Pigmentation Disorders Skin Diseases Skin and Connective Tissue Diseases

Age range

6 year–60 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients ≥ 6 years old of both genders
Early onset vitiligo (˂6m duration)
Body surface area (BSA) affected ≤2%

Exclusion criteria

Patients who received any previous treatment for vitiligo
Pregnant and lactating females
Patients with other cutaneous or systemic autoimmune diseases
Patients with contraindication to systemic corticosteroids

Treatment and study plan

Primary outcomes

Duration needed to arrest of vitiligo activity

Time frame: 6 months

Time needed for vitiligo patients to stop developing new lesions of vitiligo
Duration of maintaining vitiligo stability

Time frame: 5 years

Time before any new vitiligo lesions reappear

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

Evaluation of Early Systemic Stabilization Therapy on Recent Onset Localized Non-segmental Vitiligo

Important dates

Study start: 2015
Primary completion: 2021
Study completion: 2021
First posted: Sep 8, 2021
Registry last updated: Sep 8, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed